Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study

BACKGROUND: Regorafenib is a multi-kinase inhibitor, which was shown to be effective for patients with metastatic colorectal cancer refractory to standard therapies. However, its patterns of response has not yet been fully understood. METHODS: Clinical records of 10 patients who received regorafenib...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Ozaki, Yukinori, Shindoh, Junichi, Gonoi, Wataru, Nishioka, Yujiro, Kondoh, Chihiro, Tanabe, Yuko, Matoba, Shuichiro, Kuroyanagi, Hiroya, Hashimoto, Masaji, Takano, Toshimi
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5800281/
https://ncbi.nlm.nih.gov/pubmed/29402244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4067-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars